Cita APA

Garcia Guiñón, A., Charry, P., Jimenez, M., Sarra, J., Delgado, I., Segura de la Torre, L., . . . Fernández de Larrea, C. (2025). Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.

Citación estilo Chicago

Garcia Guiñón, Antoni, et al. Real-world Evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in Patients With Relapsed / Refractory Multiple Myeloma. 2025.

Cita MLA

Garcia Guiñón, Antoni, et al. Real-world Evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in Patients With Relapsed / Refractory Multiple Myeloma. 2025.